EIKNEikon TherapeuticsSigning up patients
A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.
Non Small Cell Lung Cancer (Squamous or Non Squamous) · Stage 4 NSCLC
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2/3
- Patients
- 750 (planned)
- Started
- Jun 15, 2026
- Main results expected
- Dec 31, 2035
- Fully finished
- Dec 31, 2040
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free survival (PFS)
Measured over: Through study completion, up to 6 years
Overall survival (OS)
Measured over: Through study completion, up to 10 years
Objective Response (OR)
Measured over: Through study completion, up to 6 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07365319 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC